AlgenScribe Secures Equity Financing and Signs Collaboration Agreement on Base Editing.

Nice and Saclay, November 2025

AlgenScribe has announced the successful completion of an equity financing round, raising €470,000. This investment will support the ongoing development of its innovative platform, which integrates synergistic molecular biology tools designed to tackle multiple challenges in the field of gene editing.

The company has entered into its first collaboration with an American foundation, marking a significant milestone. The new scientific program aims to showcase the versatility of AlgenScribe’s platform. Notably, the platform is engineered to accurately correct pathogenic DNA mutations, ranging from alterations of a few base pairs (base editing) to changes involving several thousand base pairs (gene replacement). This adaptability opens the door to a broad spectrum of applications, all utilizing the same core technological tools.

AlgenScribe reports that it has reached its initial objective of improving gene replacement efficiency. According to Frédéric Zampatti, President and Co-founder, “Our patented platform enables us to improve gene replacement efficiency in model cells by a factor exceeding our initial target of tenfold, all while maintaining good cell viability. We have confirmed these results with a renowned French academic partner who was able to easily adopt these tools in the laboratory.”

Looking ahead to early 2026, AlgenScribe anticipates promising developments, including the transfer of its tools to ex vivo applications in collaboration with partners such as the Imagine Institute. The company also aims to address other pivotal technological challenges within gene editing. To support these advancements, which are backed by the recent capital increase, AlgenScribe plans to launch a new funding round at the end of 2026 or the beginning of 2027.

In 2027, the company will prioritize proof-of-concept studies using cells derived from patients as well as small animal disease models.

About AlgenScribe

AlgenScribe SAS is dedicated to developing a gene editing platform focused on human health. Its mission is to unlock the full potential of gene editing by resolving technical challenges that limit the application of these technologies in specific contexts. The company receives support and funding from organizations including the Provence Côte d’Azur (PCA) incubator, Region Sud, Eurobiomed, Medicen, the ANR, BPI France, and YES Invest (Yvelines Essonne Saclay Invest). Legal advice is provided by the law firm STH2.

For more information, visit www.algenscribe.com or contact AlgenScribe at contact@algenscribe.com.